title: Drugs for bad bugs: confronting the challenges of antibacterial discovery.
abstract: The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets. Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action. Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.
authors.affiliation: Infectious Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Payne
authors.forename: Michael N
authors.initials: MN
authors.lastname: Gwynn
authors.forename: David J
authors.initials: DJ
authors.lastname: Holmes
authors.forename: David L
authors.initials: DL
authors.lastname: Pompliano
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects* / Q000235:genetics; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015195:Drug Design; D023281:Genomics; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents